Phase I/II study of CT-2106 in combination with infusional 5-fluorouracil/folinic Acid (5-FU/FA) (De Gramont Schedule) as second line in patients with metastatic colorectal cancer failing an oxaliplatin plus 5-FU/FA regimen.
Phase of Trial: Phase I/II
Latest Information Update: 26 Jul 2014
At a glance
- Drugs CT 2106 (Primary) ; Fluorouracil; Folinic acid
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors CTI BioPharma
- 21 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Aug 2006 The expected completion date for this trial is now 1 Apr 2007.
- 13 Nov 2005 New trial record.